Whole-body PET/CT Predicts Response to HER2-targeted Therapy in Metastatic Breast Cancer Patients itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine.
Whole-Body PET/CT Forecasts HER2 Therapy Response in Breast Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Whole-body PET/CT predicts response to HER2-targeted therapy in metastatic breast cancer patients medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.